454 next generation-sequencing outperforms allele-specific PCR, sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1057-1064

  Altimari, Annalisa ^a   De Biase, Dario ^b   De Maglio, Giovanna ^c   Gruppioni, Elisa ^a   Capizzi, Elisa ^a   Degiovanni, Alessio ^a   D'Errico, Antonia ^a   Pession, Annalisa ^b   Pizzolitto, Stefano ^c   Fiorentino, Michelangelo ^a   Tallini, Giovanni ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Colorectal cancer; Kras mutations; Next generation sequencing; Pyrosequencing; Real time polymerase chain reaction; Targeted therapy

Indexed keywords

ARGININE; GLYCINE; K RAS PROTEIN; VALINE;

ACCURACY; ARTICLE; CHIP ARRAY HYBRIDIZATION; CODON; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; EXON; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION;

EID: 84881391898     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S42369     Document Type: Article

References (23)

1. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
2. Banck MS, Grothey A. Biomarkers of resistance to epidermal growth fac-tor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2009;15:7492-7501.
3. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 2008;26 Suppl 2:Abstr 2.
4. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to bio-marker status of cetuximab plus FOLFOX-4 as first-line treatment for meta-static colorectal cancer: the OPUS study. Ann Oncol. 2011;22:1535-1546.
5. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos T. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011;154:37-49.
6. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-2019.
7. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
8. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009;27:1130-1136.
9. Gao J, Li YY, Sun PN, Shen L. Comparative analysis of dideoxy sequencing, the KRAS strip assay and pyrosequencing for detection of KRAS mutation. World J Gastroenterol. 2010;16:4858-4864.
10. Sundström M, Edlund K, Lindell M, et al. KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer. 2010;10:660-669.
11. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, Messersmith WA. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn. 2010;12:43-50.
12. Bihl MP, Hoeller S, Andreozzi MC, et al. KRAS mutations testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13. Diagn Mol Pathol. 2012;21:14-23.
13. French D, Smith A, Powers MP, Wu AH. KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. Clin Chim Acta. 2011;412: 1578-1581.
14. Lee S, Brophy VH, Cao J, et al. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in form-alin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Arch. 2012;460:141-149.
15. Gonzalez, de Castro D, Angulo B, Gomez B et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer. 2012;107:345-351.
16. Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363-365.
17. Cross J. DxS Ltd. Pharmacogenomics. 2008;9:463-467.
18. Autogenomics.com [homepage on the Internet]. Autogenomics Inc.; http://www.autogenomics.com/cancer_KRAS-BRAF.php. Available from: http://www.autogenomics.com/. Accessed June 18, 2013.
19. 454.com. 454.com [homepage on the Internet]. 454 Life Sciences, a Roche Company; http://454.com/downloads/GSJuniorSystem_Brochure. pdf. Available from: http://www.454.com/. Accessed June 18, 2013.
20. Aiom.it [homepage on the Internet]. Associazione Italiana di Onco-logia Medica; http://www.aiom.it/area+pubblica/area+medica/ prodotti+scientifici/position+paper/Raccomandazioni%20per%20 l'analisi%20mutazionale%20del%20gene%20KRAS%20nel%20 carcinoma%20del%20colon-retto/1,1006,1,. Available from: http://www.Aiom.it/. Accessed June 18, 2013.
21. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453:417-431.
22. Hostein I, Lamy A, Faur N, et al. The detection of double mutations in KRAS depends on the mutation-detection assay used. Clin Chem. 2011;57: 1077-1079.
23. Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from Gefitinib treatment for advanced non small cell lung cancer. J Clin Oncol. 2011;29:3316-3321.